Yusuke Ono

Dr. Yusuke Ono

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
KNKazumasa Nagai
Kazumasa Nagai
YMYusuke Mizukami
Yusuke Mizukami
YOYuko Omori
Yuko Omori
TKToshifumi Kin
Toshifumi Kin
KYKei Yane
Kei Yane
AKAkio Katanuma
Akio Katanuma

10 July 2017 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
YOYusuke Ono
Yusuke Ono
ASAyumu Sugitani
Ayumu Sugitani
HKHidenori Karasaki
Hidenori Karasaki
MOMunehiko Ogata
Munehiko Ogata
RNReo Nozaki
Reo Nozaki
YMYusuke Mizukami
Yusuke Mizukami
Genetic alterations responsible for the initiation of cancer may serve as immediate biomarkers for early diagnosis. Plasma levels of cell‐free DNA (cfDNA) in patients with cancer are higher than those in healthy individuals; however, the major technical challenge for the widespread implementation of cfDNA genotyping as a diagnostic tool is the insufficient sensitivity and specificity of detecting early‐stage tumors that shed low amounts of cfDNA. To establish a protocol for ultrasensitive droplet digital polymerase chain reaction (ddPCR) for quantification of low‐frequency alleles within a limited cfDNA pool, two‐step multiplex ddPCR targeting eight clinically relevant mutant KRAS variants was examined. Plasma samples from patients with colorectal (n = 10) and pancreatic cancer (n = 9) were evaluated, and cfDNA from healthy volunteers (n = 50) was utilized to calculate reference intervals. Limited cfDNA yields in patients with resectable colorectal and pancreatic cancers did not meet the requirement for efficient capture and quantification of rate mutant alleles by ddPCR. Eight preamplification cycles followed by a second‐run ddPCR were sufficient to obtain approximately 5000–10 000 amplified copies per ng of cfDNA, resolving the subsampling issue. Furthermore, the signal‐to‐noise ratio for rare mutant alleles against the extensive background presented by the wild‐type allele was significantly enhanced. The cutoff limit of reference intervals for mutant KRAS was determined to be ~ 0.09% based on samples from healthy individuals. The modification introduced in the ddPCR protocol facilitated the quantification of low‐copy alleles carrying driver mutations, such as oncogenic KRAS, in localized and early‐stage cancers using small blood volumes, thus offering a minimally invasive modality for timely diagnosis.

Verified
Journal Article
Open access
PDF file
KTKenzui Taniue
Kenzui Taniue
TTTanzina Tanu
Tanzina Tanu
YSYuki Shimoura
Yuki Shimoura
SMShuhei Mitsutomi
Shuhei Mitsutomi
HHHan Han
Han Han
NANobuyoshi Akimitsu
Nobuyoshi Akimitsu
The RNA exosome is a multi-subunit ribonuclease complex that is evolutionally conserved and the major cellular machinery for the surveillance, processing, degradation, and turnover of diverse RNAs essential for cell viability. Here we performed integrated genomic and clinicopathological analyses of 27 RNA exosome components across 32 tumor types using The Cancer Genome Atlas PanCancer Atlas Studies’ datasets. We discovered that the EXOSC4 gene, which encodes a barrel component of the RNA exosome, was amplified across multiple cancer types. We further found that EXOSC4 alteration is associated with a poor prognosis of pancreatic cancer patients. Moreover, we demonstrated that EXOSC4 is required for the survival of pancreatic cancer cells. EXOSC4 also repressed BIK expression and destabilized SESN2 mRNA by promoting its degradation. Furthermore, knockdown of BIK and SESN2 could partially rescue pancreatic cells from the reduction in cell viability caused by EXOSC4 knockdown. Our study provides evidence for EXOSC4-mediated regulation of BIK and SESN2 mRNA in the survival of pancreatic tumor cells.

19 November 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
RYRyohei Yoshida
Ryohei Yoshida
TSTakaaki Sasaki
Takaaki Sasaki
YUYasuhiro Umekage
Yasuhiro Umekage
STSachie Tanno
Sachie Tanno
YOYusuke Ono
Yusuke Ono
YOYoshinobu Ohsaki
Yoshinobu Ohsaki
On-target resistance mechanisms found in one-third of patients receiving anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are secondary ALK mutations in ALK-rearranged non-small cell lung cancer (NSCLC). There are large variations in the resistant mutations, unlike the epithelial growth factor receptor (EGFR) T790 M seen with the use of EGFR-TKIs. Liquid biopsy approaches using cell-free DNA (cfDNA) are used for screening and monitoring of mutations in NSCLC. However, feasible protocol for the simultaneous detection of multiple secondary ALK mutations using droplet digital PCR (ddPCR) has not been developed. An efficient strategy using cfDNA in cancer diagnostics, the development of more accurate and cost-effective tools to identify informative multiple secondary ALK mutations is clinically required. To establish a feasible assay to monitor ALK-TKI resistance mutations, we first evaluated the feasibility of ddPCR-based screening for cfDNA mutation detection of 10 distinct secondary ALK mutations. Positive samples were then re-analyzed using mutation-specific probes to track the growth of mutation clones with a high sensitivity. Blood samples from seven ALK-positive patients were analyzed using the ddPCR protocol. Secondary G1202R ALK mutations were identified in 2 of 7 patients by the screening assay. Using the mutation-specific probes, monitoring the resistant clone during the clinical course of the disease was well demonstrated in each of the patients. The protocol for ddPCR-based liquid biopsy has a feasibility for the screening of secondary ALK-TKI resistance mutations and offers a tool for a cost-effective monitoring of progression in NSCLC.

23 March 2023 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
CMChiho Maeda
Chiho Maeda
YOYusuke Ono
Yusuke Ono
AHAkihiro Hayashi
Akihiro Hayashi
KTKENJI TAKAHASHI
KENJI TAKAHASHI
KTKenzui Taniue
Kenzui Taniue
YMYusuke Mizukami
Yusuke Mizukami

5 February 2022 in Gene
Verified
Journal Article
Closed access
YOYusuke Ono
Yusuke Ono
TMTaku Maejima
Taku Maejima
YOYusuke Ono
Yusuke Ono
TITakahiro Ito
Takahiro Ito
SFShigeru Furukawa
Shigeru Furukawa
AMAtsuo Maemoto
Atsuo Maemoto